Research status and progress on neoadjuvant therapy for esophageal cancer
10.3760/cma.j.cn113030-20210604-00215
- VernacularTitle:食管癌新辅助治疗研究现状与进展
- Author:
Junge ZHU
1
;
Jianbin LI
;
Yingjie ZHANG
Author Information
1. 山东第一医科大学（山东省医学科学院）研究生部，济南 250117
- Keywords:
Esophageal neoplasm/neoadjuvant chemotherapy;
Esophageal neoplasm/neoadjuvant chemoradiotherapy;
Esophageal neoplasm/targeted therapy;
Esophageal neoplas
- From:
Chinese Journal of Radiation Oncology
2022;31(4):389-394
- CountryChina
- Language:Chinese
-
Abstract:
China is a country with high incidence of esophageal cancer. In recent years, with the deepening research, the value of neoadjuvant therapy in locally advanced resectable esophageal cancer has been widely approved by clinicians, compared with surgery alone or adjuvant therapy. However, the survival results of different neoadjuvant therapy options may be quite different, and many problems remain unresolved. In this article, a systemic literature review was carried out to summarize the radiotherapy target, radiotherapy dose, chemotherapy regimen of neoadjuvant chemoradiotherapy and time to surgery, as well as review the research status and progress on targeted therapy and immunotherapy as neoadjuvant therapy for esophageal cancer.
